cobas® CT/NG v2.0 Test4

Performance validated for recommended populations and specimen types with the

VENUS ( Vaginal, Endocervical  and Urine Screening) clinical study.

    Designed to deliver accurate results

    • Dual-probe, single-tube multiplex assay design with automatic internal control
    • Dual-target design to detect all major CT/NG strains, ensuring true positive results
    • Built-in internal control validates a negative result
    • Built-in contamination control to minimize the risk of false positive result

    Supports CDC recommendation for testing with a wide range of specimen types 

    (consult with your laboratory)5

    • Vaginal swabs specimens (provider-collected or self-collected)
    • Endocervical swab specimens
    • Urine specimens (male and female)
    • Liquid-based cytology specimens

    Offers robust clinical validation: VENUS clinical study

    • Validated in low- and high-prevalence populations
    • Validation included pregnant women

    The cobas® CT/NG v2.0 Test has been evaluated in pregnant women, which remains a critical screening population according to the 2015 CDC Screening Recommendations.

    1. Sexually Transmitted Diseases Surveillance 2014. CDC Division of STD Prevention. December 2014.
    2. The State of Health Care Quality 2015, HEDIS Measure of care.
    3. Sexually Transmitted Diseases Treatment Guidelines, 2015. CDC. June 5, 2015.
    4. cobas® CT/NG v2.0 Test [package insert]. Indianapolis, IN. Roche Diagnostics; 2015.
    5. Recommendation for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae, 2014. MMWR. 2014;63(2).